

1 Full title:

2 **Effect of delays in concordant antibiotic treatment on mortality in patients with hospital-**
3 **acquired *Acinetobacter* spp. bacteremia: a 13-year retrospective cohort**

4

5 Short Title: **Delays in concordant antibiotic treatment for *Acinetobacter* spp. bacteremia**

6

7 Cherry Lim^{1,2} MSc, Mo Yin^{1,2,3} MD, Prapit Teparrukkul⁴ MD, Maliwan Hongsuwan¹ PhD, Nicholas

8 P.J. Day^{1,2} FRCP, Direk Limmathurotsakul^{1,2} PhD, Ben S Cooper^{1,2} PhD

9

10 ¹Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,

11 Thailand

12 ²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of

13 Oxford, United Kingdom

14 ³Division of infectious disease, University Medicine Cluster, National University Hospital, Singapore,

15 Singapore.

16 ⁴Department of Internal Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand

17

18 **Corresponding author:** Cherry Lim, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of

19 Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand. Tel: +66 2

20 203 6333, Fax: +66 2 354 9169, e-mail: cherry@tropmedres.ac

21

22 **Keywords:** empirical antibiotic treatment, patient mortality, *Acinetobacter* spp., bacteremia, causal

23 inference

24

25

26 **Abstract** (249 words)

27 **Background**

28 Therapeutic options for multidrug-resistant *Acinetobacter* spp. are limited, and resistance to last resort
29 antibiotics in hospitals is increasing globally. Quantifying the impact of delays in concordant antibiotic
30 treatment on patient mortality is important for designing hospital antibiotic policies.

31

32 **Methods**

33 We included patients with *Acinetobacter* spp. hospital-acquired bacteremia (HAB) in a hospital in
34 Thailand over a 13-year period. For each day of stay following the first positive blood culture we
35 considered antibiotic treatment to be concordant if the isolated organism was susceptible to at least one
36 antibiotic given. We used marginal structural models with inverse-probability weightings to determine
37 the association between delays in concordant treatment and 30-day mortality.

38

39 **Results**

40 Between January 2003 and December 2015, 1,203 patients had HAB with *Acinetobacter* spp., of which
41 682 patients (56.7%) had one or more days of delay in concordant treatment. These delays were
42 associated with an absolute increase in 30-day mortality of 6.6% (95% CI 0.2%-13.0%), from 33.8% to
43 40.4%. Crude 30-day mortality was substantially lower in patients with three or more days of delays in
44 concordant treatment compared to those with one to two days of delays. Accounting for confounders
45 and immortal time bias resolved this paradox, and showed similar 30-day mortality for one, two and
46 three or more days of delays.

47

48 **Conclusions**

49 Delays in concordant antibiotic treatment were associated with a 6.6% absolute increase in mortality
50 among patients with hospital-acquired *Acinetobacter* spp. bacteremia. If this association is causal,
51 switching fifteen patients from discordant to concordant initial treatment would be expected to prevent
52 one death.

53

54

55

56 **Funding**

57 The Mahidol Oxford Tropical Medicine Research Unit (MORU) is funded by the Wellcome Trust [grant
58 number 106698/Z14/Z]. CL is funded by a Wellcome Trust Research Training Fellowship [grant number
59 206736/Z/17/Z]. MY is supported by a Singapore National Medical Research Council Research
60 Fellowship [grant number NMRC/Fellowship/0051/2017]. BSC is funded by the UK Medical Research
61 Council and Department for International Development [grant number MR/K006924/1]. DL is funded
62 by a Wellcome Trust Intermediate Training Fellowship [grant number 101103]. The funder has no role
63 in the design and conduct of the study, data collection, or in the analysis and interpretation of the data.

64

65

66 **Introduction (489 words)**

67 Hospital-acquired bloodstream infection related to multidrug-resistant (MDR) *Acinetobacter* spp. is
68 associated with increased patient mortality, especially in developing countries. The proportion of
69 hospital-acquired *Acinetobacter* spp. bacteremias that are MDR can be as high as 75%, and attributable
70 mortality has been estimated to range from 18-41% in developing countries.¹⁻⁵ In a previous study
71 conducted in Thailand, around 15,000 excess deaths per year were estimated to be related to MDR
72 *Acinetobacter* spp.² Therapeutic options for treating MDR *Acinetobacter* spp. infections are limited.
73 Carbapenem, colistin, and tigecycline are currently the last resort antibiotics for drug-resistant
74 *Acinetobacter* spp. bloodstream infection, and increasing resistance to these antibiotics has been reported
75 in developing countries.^{6,7} The spread of resistant pathogens can be fueled by the overuse of broad-
76 spectrum antibiotics in hospital settings,⁸ and *Acinetobacter* spp. has an ability to assemble different
77 mechanisms of resistance.⁹ The World Health Organization recommends that hospital antibiotic policies
78 are developed based on local evidence, with the aims of minimizing morbidity and mortality due to
79 infections, preserving the effectiveness of antimicrobial agents for treatment purposes, and preventing
80 the spread of microbial infections.¹⁰ A quantitative understanding of the impact of delays in concordant
81 antibiotic treatment on patient mortality among those with hospital-acquired *Acinetobacter* spp.
82 bloodstream infection is important for designing hospital antibiotic policies in areas with a high incidence
83 of drug-resistant *Acinetobacter* spp. infection.

84

85 Randomized controlled trials are the “gold standard” design to study the causal relationship between a
86 treatment and an outcome. However, it would be unethical to intentionally delay the provision of
87 concordant antibiotic treatment to a patient. Therefore, an observational cohort study is likely to be the
88 best way to determine the impact of delays in concordant antibiotic treatment on patient outcomes. There
89 are, however, intrinsic limitations with such an approach. Firstly, hospitalized patients vary in severity
90 of underlying illness, which in turn could affect antibiotic prescription behavior and the probability of
91 acquiring drug-resistant infections. At the same time, severity of underlying illness is an important
92 determinant of mortality. This suggests severity of underlying illness is a key confounder to consider
93 when studying the causal relationship between antibiotic treatment and patient in-hospital mortality, and
94 should be adjusted for in the analysis. However, measures of patient severity are not routinely collected
95 in most resource-limited hospital settings. Secondly, antibiotic treatment may change over the course of

96 an infection, and these changes will often be related to the time-varying clinical severity of the patient,
97 which could be a confounder for the current treatment and a mediator for the future treatment (Box 1).
98 Finally, patients may die or be discharged from the hospital before the empirical treatment is completed,
99 and excluding these patients from the final analysis could introduce immortal time bias.¹¹⁻¹³

100

101 In this study, our objective is to study the relationship between days of delay in concordant antibiotic
102 treatment and patient mortality by performing an analysis on observational data accounting for these
103 distorting factors, aiming, as far as possible, to emulate a randomized trial.

104 **Methods (1008 words)**

105

106 **Study design and participants**

107 We identified, from a 13-year retrospective cohort, patients with hospital-acquired bacteremia (HAB)
108 related to *Acinetobacter* spp. in Sunpasitthiprasong Hospital, Thailand. This is a provincial hospital with
109 1,500 beds. The hospital has a microbiology laboratory that performs culture and isolate identification
110 and antibiotic susceptibility tests on a daily basis. The number of blood cultures performed in 2003 was
111 11,584 and in 2015 was 56,719. Patients were eligible for inclusion in this study if they had stayed in the
112 hospital longer than 2 calendar days when a blood sample with growth of *Acinetobacter* spp. was
113 collected. During the study period, bacterial culture was performed using standard methodologies for
114 bacterial identification and susceptibility testing based on guidelines of the Bureau of Laboratory Quality
115 and Standards, Ministry of Public Health, Thailand.¹⁴ Antimicrobial susceptibility was determined using
116 the disk diffusion method based on Clinical and Laboratory Standards Institute (CLSI) guidelines.¹⁵ The
117 first episode of *Acinetobacter* spp. bloodstream infection (BSI) per eligible patient was included in the
118 analysis. If more than one isolate of *Acinetobacter* spp. with different susceptibility profiles was
119 identified, only the isolate resistant to the largest number of antibiotics tested was included in the
120 analysis. Hospital admission and microbiology databases were merged to identify the cohort of patients.
121 Data on antibiotic prescription, ICD 10 diagnosis, and demographic information of this cohort were then
122 collected for analysis.

123

124 The study was approved by the Institutional Review Board of Sunpasitthiprasong Hospital. STROBE
125 recommendations were followed (Supplementary 1).

126

127 **Exposure groups**

128 We considered any antibiotics prescribed within three days of the first blood sample collected and with
129 *Acinetobacter* spp. isolated to represent empirical treatment. This is because microbiological
130 identification and antibiotic susceptibility testing usually require three days. An antibiotic regimen was
131 defined as concordant if susceptibility testing indicated that the isolated organism was susceptible to at
132 least one of the antibiotics given. Otherwise the regimen was defined as discordant. Concordance of the
133 antibiotic treatment was determined for each eligible patient on the day of blood sample collection (t=0),

134 one calendar day after blood sample collection ($t=1$), and two calendar days after blood sample collection
135 ($t=2$).

136

137 **Outcomes**

138 The primary outcome is in-hospital all-cause mortality within 30 days of the first blood sample collected
139 and with *Acinetobacter* spp. isolated. If a patient was discharged alive from the hospital before Day 30
140 or remained in the hospital on Day 30, then the patient was considered to have survived in the primary
141 analysis.

142

143 **Covariate selection**

144 Potential confounders were identified using a directed acyclic graph to represent the presumed causal
145 relationships between antibiotic treatment and patient mortality (Supplementary 2).¹⁶ The key potential
146 baseline confounders identified were severity of underlying illness,¹⁷ antibiotic resistance pattern of the
147 *Acinetobacter* spp. isolated from the blood sample, year in which the blood samples were collected, and
148 specialty of the attending physician. We used the time between date of admission and date of blood
149 sample collection, admission to intensive care unit (ICU) on the day of hospital admission, the number
150 of days on antibiotic treatment prior to blood sample collection, and age-stratified Charlson comorbidity
151 index (CCI) score as surrogates of severity of underlying illness. The CCI scores were calculated from
152 the ICD 10 codes given to each patient by the attending physicians.¹⁸ MDR *Acinetobacter* spp. was
153 defined as previously described.¹⁹ As data on specialty of the attending physician is not routinely
154 collected in the electronic record, we used the department in which the patient was treated on the day of
155 blood collection as a proxy variable. A time-varying confounder that could affect changes in empirical
156 antibiotic treatment post blood sample collection is severity of infection, which could be affected by the
157 history of treatment and itself may influence the decision on future treatment. The prescription of a
158 vasopressor and transfer to ICU during the infection within the analysis time period were used to
159 represent severity of the infection and both coded as binary time varying variables. Patient demographic
160 information, age and gender, were also included as covariates.

161

162 **Statistical analysis**

163 The effects of delays in concordant empirical antibiotic treatment on 30-day mortality were estimated
164 using marginal structural models.²⁰ We performed two analyses. The first analysis was to evaluate the
165 impact of one or more days of delays in concordant antibiotic treatment. A propensity score for each
166 patient was calculated to represent the probability of being prescribed with concordant antibiotic on the
167 day of blood collection using a logistic regression model adjusting for the pre-specified confounders and
168 using fractional polynomials to account for non-linear relationships. The propensity scores were then
169 used to calculate stabilized inverse probability weights (IPW), which were applied to a marginal
170 structural model. The second analysis was to evaluate the effect of one-day, two-day, and three or more
171 days of delays in concordant antibiotic treatment. We applied two sets of IPWs to a marginal structural
172 model. Firstly, a propensity score for each patient was calculated to represent the probability of being
173 prescribed with a concordant antibiotic treatment on the day of blood sample collection, one day after,
174 and two days after. The propensity scores were then used to calculate stabilized IPWs. Secondly, to
175 emulate a randomized controlled trial with treatment regimen assigned on enrolment, patients who were
176 discharged or died before completing the treatment were treated as censored observations, and propensity
177 scores were calculated for being uncensored in the cohort.¹³ We then applied a marginal structural logistic
178 regression model with the (multiplicative) total stabilized IPWs to estimate the marginal probability of
179 30-day mortality under each treatment regimen. Statistical analyses were done using STATA, version
180 15.1 (StataCorp LP, College station, Texas, USA). All analysis code is provided in Supplementary 3. A
181 simulation study was also performed and confirmed that the procedure could recover the expected 30-
182 day mortality associated with delays in concordant antibiotic treatment.

183

184 It is a common practice in Thailand for moribund patients to be discharged and to die at home. This may
185 cause mis-classification of outcomes. To address the issue, we performed a sensitivity analysis
186 (Supplementary 5) and patients who were either discharged without improvement or who rejected
187 treatment and discharged were classified into the group assumed to have died within 30 days.

188

189 **Role of the funding source**

190 The funders of the investigators and study had no role in the study design, data collection, data analysis,
191 data interpretation, or writing of the manuscript. CL, DL, and PT had full access to the data described in
192 the study. The corresponding author has the final decision to submit for publication.

193 **Results (834 words)**

194 **Patients**

195 Between January 1, 2003, and December 31, 2015, 1,203 patients had a blood sample collected yielding
196 *Acinetobacter* spp after two days of hospitalization (Figure 1). Amongst the eligible patient cohort, 521
197 patients had no delays in concordant antibiotic treatment (i.e. patients had concordant treatment on the
198 day of blood sample collection); 224 patients had a one-day delay in concordant antibiotic treatment;
199 119 patients had a two-day delay in concordant antibiotic treatment; and 339 patients had three or more
200 days of delays in concordant antibiotic treatment.

201

202 Patient characteristics varied across the four groups of exposures (Table 1). The proportion of patients
203 admitted to ICU wards on the day of hospitalization was highest among those having a one-day delay in
204 concordant antibiotic treatment (159 of 224 patients; 71.0%), followed by those having a two-day delay
205 (72 of 119 patients, 60.5%). The proportion of patients with MDR *Acinetobacter* spp. isolates was highest
206 among those who had a one-day delay in concordant antibiotic treatment (206 of 224; 92.0%), followed
207 by those who had three or more days of delay (302 of 339 patients; 89.1%). The cumulative days on
208 antibiotics prior to blood collection also varied across the four groups of patients. The patients who had
209 no delays in concordant antibiotic treatment were on antibiotics the longest prior to blood sample
210 collection, with a median of 8 (IQR: 5-15) days.

211

212 The most commonly prescribed antibiotics on the day of blood sample collection were carbapenems
213 (n=312) followed by ceftazidime (n=121). Of 467 patients who died within 30 days after blood sample
214 collection, 294 patients did not have a concordant antibiotic prescription on the day of blood sample
215 collection. Of those patients, 33.7% (99/294) had a prescription of a carbapenem, 16.0% (47/294) did
216 not have an antibiotic prescription, and 9.9% (29/294) had a prescription of a third-generation
217 cephalosporin. Of 736 patients who survived for at least 30 days after the first positive blood sample was
218 collected, 24.2% (178/736) had a prescription of a carbapenem on the day of blood sample collection,
219 17.1% (126/736) had a prescription of a third-generation cephalosporin, and 10.1% (74/736) did not have
220 an antibiotic prescription.

221

222 **Antibiotic treatment concordance on the day of blood sample collection and 30-day in-hospital**
223 **mortality**

224 Receiving concordant antibiotic treatment on the day of blood collection was associated with reduced
225 30-day mortality, after adjusting for the pre-specified confounders. Patients given concordant antibiotic
226 treatment on the day of blood collection had an expected 30-day mortality of 33.8% (95% CI 29.1%-
227 38.5%), compared with an expected 30-day mortality of 40.4% (95% CI 36.0%-44.7%) in those not
228 treated with concordant antibiotics. The absolute difference was 6.6% (95% CI 0.2%-13.0%).

229

230 **Days of delays in concordant antibiotic treatment and 30-day in-hospital mortality**

231 The crude 30-day in-hospital all-cause mortality was highest among those with a one-day delay in
232 concordant antibiotic treatment (133 of 224 patients; 59.4%), and lowest among those with three or more
233 days of delays in concordant antibiotic treatment (102 of 339 patients; 30.1%) [Table 1]. The discharge
234 pattern of patients under different treatment groups varied over the three days of the initial treatment
235 period (Figure 2). Amongst the 1,203 eligible patients, 236 (19.6%) patients either died or were
236 discharged from the hospital one day after blood was collected for culture and, of those patients, 63.6%
237 died within the hospital.

238

239 The marginal structural model adjusting for baseline confounders, time-varying confounders, and
240 immortal time bias resolved paradoxical observations in the crude data (Table 2). While the crude
241 analysis suggested that patients with three or more days of delays in concordant antibiotic treatment had
242 the lowest mortality, the adjusted analysis found that the expected mortality was the lowest if the patients
243 had no delays, though found no evidence of increasing mortality with increasing delays. However,
244 uncertainty was large. Absolute differences in mortality between no delays in concordant antibiotic
245 treatment and a one-day delay, a two-day delay, and three or more days of delays were 3.0% (95% CI -
246 12.0%-18.0%); 11.3% (95% CI -3.0%-25.6%); and 1.1% (95% CI -7.8%-10.0%), respectively.

247

248 **Sensitivity analysis**

249 Under the assumption that patients discharged within 30 days of the first positive blood culture either
250 without improvement or having rejected treatment died within 30 days, a similar effect of delayed
251 concordant treatment was observed. If patients were given a concordant antibiotic treatment on the day

252 of blood sample collection, the expected marginal probability of developing a detrimental outcome
253 (death or discharge without improvement) would be 58.8% (95% CI 53.8%-63.9%), which is lower than
254 if they were not given a concordant antibiotic treatment (62.0% [95% CI 57.7%-66.4%]). The difference
255 was 3.2% (95% CI -3.5%-9.9%). The estimated marginal probabilities of developing a detrimental
256 outcome (death or discharge without improvement) within 30 days of blood collection were 64.6% (95%
257 CI 56.8%-72.4%), 63.2% (95% CI 50.4%-75.9%), 68.5% (95% CI 56.1%-80.8%), 63.4% (95% CI
258 58.5%-68.3%) for no delays, a one-day delay, a two-day delay, and three or more days of delays in
259 concordant antibiotic treatment respectively (Supplementary 5). The estimated impacts of the treatment
260 regimens on detrimental outcomes were similar to the effects on 30-day in-hospital mortality
261 (Supplementary 6).

262 **Discussion (908 words)**

263 After adjusting for measured confounders, we found that delays in concordant antibiotic treatment of one
264 or more days were associated with an absolute increase of 6.6% in 30-day mortality from 33.8% to
265 40.4%. If this increase is caused by the delay in concordant treatment, it would indicate that we would
266 need to switch empirical antibiotic treatment from discordant to concordant in fifteen patients in order to
267 prevent one 30-day death. There was no evidence of a dose response relationship between number of
268 days of delays in concordant antibiotics and 30-day mortality.

269

270 The immortal time bias observed in this cohort is a common phenomenon, and needs to be considered in
271 any study comparing treatment regimens where the observed treatment durations vary.^{11,13} In this study
272 empirical antibiotic treatment over a period of three days after blood collection was considered and only
273 patients who survived up to three days after blood was collected could be classified into the group of “ ≥ 3
274 days of delays in concordant antibiotic treatment”. Hence, by definition, they cannot have died within
275 the first 3 days and for this time period they are effectively “immortal”. This bias will tend to make them
276 appear to survive longer compared to the reference group (no delays in concordant antibiotic treatment).
277 This is reflected in the paradoxical observation that the crude all-cause 30-day mortality was lowest
278 among patients with ≥ 3 days of delays in concordant antibiotic treatment. Several analytical approaches
279 have been described to adjust for immortal time bias.¹¹ For example, an analysis on 964 patients with
280 *Staphylococcus aureus* bacteremia in hospitals in Germany used multivariable Cox regression model
281 with an interaction term of exposure and time to correct for immortal time bias and to study the impact
282 of combined antibiotic therapy on patient survival.²¹ However, even in the absence of unmeasured
283 confounding, causal interpretations of hazard ratios are not straightforward.²²

284

285 Previous analyses have evaluated the impact of delayed antibiotic treatment on outcomes for patients
286 with bacteremia related to *Acinetobacter* spp., but appropriate adjustment for both time-varying and
287 immortal time biases has been lacking.²³⁻³⁰ In a retrospective study on 1,423 patients in hospitals in the
288 United States, pneumonia and/or sepsis patients who received inappropriate empiric therapy (defined as
289 no antibiotic treatment covering the organism administered within 2 days of the first positive culture)
290 had increased mortality (adjusted relative risk ratio was 1.85 [95% CI 1.35-2.54]).³⁰ The study included
291 patients with both community-acquired and healthcare-associated infections; patients with fewer than 2

292 days of hospitalization were excluded from the analysis. A generalized logistic regression model
293 adjusting for patient demographics, comorbidities, severity of illness, and infection origin was used.³⁰ A
294 study in Taiwan on 252 patients with ICU-acquired bloodstream infections caused by *Acinetobacter*
295 *baumannii* suggested appropriate antibiotic therapy (defined as administration of at least one antibiotic
296 treatment that is appropriate in type, route and dosage within 48 hours of bacteremia onset) reduced 14-
297 day mortality (adjusted odds ratio was 0.22 [95% CI 0.10-0.50]).²⁷ The analysis used a multivariable
298 logistic regression model adjusted for APACHE II score measured two days prior to bacteremia onset
299 and malignancy. In this study, among those with APACHE II score >35 more than 70% of patients died
300 within 24 hours in the inappropriate antibiotic group and in the appropriate treatment group no patient
301 died within the initial 48 hours treatment period.²⁷ Some of the reported differences in survival
302 probability are therefore expected to be due to immortal-time biases.

303

304 In most previous studies antibiotic use has been considered as a binary variable and switching of
305 antibiotic regimens due to changes in clinical symptoms has been neglected.³¹ In hospitals in resource-
306 limited settings, antibiotics are sometimes prescribed even before a clinical specimen is taken for culture,
307 and switching regimen in response to severity of infection is common.³¹ This change in regimen
308 determined by clinical symptoms, if not adjusted for using appropriate methods for time-varying
309 confounders, may also lead to biases.²⁰ Marginal structural models have been used to adjust for time-
310 varying confounders in a previous study of the association between appropriate antibiotic treatment for
311 bacteremia on the day the blood culture was taken and mortality and discharge.³² The previous study
312 found no evidence for a protective effect of appropriate empirical antibiotic treatment on mortality and
313 discharge, but confidence intervals were wide.³² Differences in bacterial species considered, patient
314 characteristics and clinical setting make direct comparison with the current study inappropriate.

315

316 Our study has limitations. Firstly, data on severity of infections were not routinely collected, and this is
317 typically the case in LMIC settings. We used admission to ICU and prescription of vasopressor as proxy
318 variables for the severity of infection. These proxy variables will only imperfectly represent the severity
319 of infection and residual confounding is to be expected; however, both are specific in representing severe
320 clinical conditions. Secondly, despite the relatively large sample size, the power to detect a dose-response
321 relationship in the four regimens under evaluation might be low. This is reflected in the wide confidence

322 intervals in our expected mortality under each regimen. Hence, although we do not find evidence of a
323 dose response relationship between delays in concordant treatment and mortality, the results do not rule
324 out the possibility.

325

326 In conclusion, we observed a 6.6% absolute increase in mortality among patients with hospital-acquired
327 *Acinetobacter* spp. bacteremia when concordant antibiotic treatment was delayed for one or more days.

328 Accounting for confounding and immortal time biases is necessary when attempting to estimate causal
329 effects of delayed concordant treatment and, in this case, helped resolve paradoxical results in crude data.

330

331 **References**


- 332 1. Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-
333 years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area
334 in 2015: a population-level modelling analysis. *Lancet Infect Dis* 2019;19:56-66.
- 335 2. Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of multidrug-resistant
336 bacterial infection in a developing country. *Elife* 2016;5.
- 337 3. Deris ZZ, Shafei MN, Harun A. Risk factors and outcomes of imipenem-resistant
338 *Acinetobacter* bloodstream infection in North-Eastern Malaysia. *Asian Pac J of Trop Biomed*
339 2011;1:313-5.
- 340 4. Kumar A, Randhawa VS, Nirupam N, Rai Y, Saili A. Risk factors for carbapenem-resistant
341 *Acinetobacter baumannii* blood stream infections in a neonatal intensive care unit, Delhi, India. *J Infect*
342 *in Dev Ctries* 2014;8:1049-54.
- 343 5. Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and epidemiological significance of
344 carbapenem resistance in *Acinetobacter baumannii* infections. *Antimicrob Agents Chemother*
345 2016;60:3127-31.
- 346 6. Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant *Acinetobacter baumannii*:
347 epidemiology, surveillance and management. *Expert Rev Anti Infect Ther* 2013;11:383-93.
- 348 7. Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-
349 year trends from the SENTRY antimicrobial surveillance program. *Antimicrob Agents Chemother*
350 2019;63:e00355-19.
- 351 8. Chatterjee A, Modarai M, Naylor NR, et al. Quantifying drivers of antibiotic resistance in
352 humans: a systematic review. *Lancet Infect Dis* 2018;18:e368-e78.
- 353 9. Munoz-Price LS, Weinstein RA. *Acinetobacter* infection. *N Engl J Med* 2008;358:1271-81.
- 354 10. World Health Organization. Step-by-step approach for development and implementation of
355 hospital antibiotic policy and standard treatment guideline. New Delhi: WHO Regional Office for
356 South-East Asia; 2011.
- 357 11. Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-
358 dependent study entries and exposures in cohort studies can easily be sources of different and
359 avoidable types of bias. *J Clin Epidemiol* 2012;65:1171-80.

- 360 12. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents
361 immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol*
362 2016;79:70-5.
- 363 13. Hernan MA. How to estimate the effect of treatment duration on survival outcomes using
364 observational data. *BMJ* 2018;360:k182.
- 365 14. Opartkiattikul N, Bejrachandra S. The external quality assessment schemes in Thailand.
366 *Rinsho Byori* 2002;50:121-5.
- 367 15. Clinical and Laboratory Standards Institute. Analysis and presentation of cumulative
368 antimicrobial susceptibility test data, 4th Edition. 2014.
- 369 16. Hernán MA, Robins JM. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC;
370 2020:69-80.
- 371 17. Limmathurotsakul D, Dunachie S, Fukuda K, et al. Improving the estimation of the global
372 burden of antimicrobial resistant infections. *Lancet Infect Dis* 2019;19:e392-8.
- 373 18. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10
374 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol*
375 2004;57:1288-94.
- 376 19. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant
377 and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for
378 acquired resistance. *Clin Microbiol Infect* 2012;18:268-81.
- 379 20. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in
380 epidemiology. *Epidemiology* 2000;11:550-60.
- 381 21. Rieg S, Joost I, Weiss V, et al. Combination antimicrobial therapy in patients with
382 *Staphylococcus aureus* bacteraemia—a post hoc analysis in 964 prospectively evaluated patients. *Clin*
383 *Microbiol Infect* 2017;23:406 e1- e8.
- 384 22. Hernan MA. The hazards of hazard ratios. *Epidemiology* 2010;21:13-5.
- 385 23. Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N. Impact of early appropriate
386 antimicrobial therapy on survival in *Acinetobacter baumannii* bloodstream infections. *Int J Antimicrob*
387 *Agents* 2009;34:575-9.

- 388 24. Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with
389 carbapenem-resistant *Acinetobacter baumannii* bacteremia. *J Microbiol Immunol Infect* 2012;45:356-
390 62.
- 391 25. Kim YJ, Kim SI, Hong KW, Kim YR, Park YJ, Kang MW. Risk factors for mortality in
392 patients with carbapenem-resistant *Acinetobacter baumannii* bacteremia: impact of appropriate
393 antimicrobial therapy. *J Korean Med Sci* 2012;27:471-5.
- 394 26. de Gouvea EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on
395 mortality in solid organ transplant recipients with *Acinetobacter baumannii* infection. *BMC Infect Dis*
396 2012;12:351.
- 397 27. Lee YT, Kuo SC, Yang SP, et al. Impact of appropriate antimicrobial therapy on mortality
398 associated with *Acinetobacter baumannii* bacteremia: relation to severity of infection. *Clin Infect Dis*
399 2012;55:209-15.
- 400 28. Kuo SC, Lee YT, Yang SP, et al. Evaluation of the effect of appropriate antimicrobial therapy
401 on mortality associated with *Acinetobacter nosocomialis* bacteraemia. *Clin Microbiol Infect*
402 2013;19:634-9.
- 403 29. Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH. Risk factors and outcome analysis of
404 *Acinetobacter baumannii* complex bacteremia in critical patients. *Crit Care Med* 2014;42:1081-8.
- 405 30. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance,
406 inappropriate empiric therapy, and hospital mortality in *Acinetobacter baumannii* pneumonia and
407 sepsis. *Crit Care* 2016;20:221.
- 408 31. Munoz-Price LS, Frencken JF, Tarima S, Bonten M. Handling time-dependent variables:
409 antibiotics and antibiotic resistance. *Clin Infect Dis* 2016;62:1558-63.
- 410 32. Pouwels KB, Van Kleef E, Vansteelandt S, et al. Does appropriate empiric antibiotic therapy
411 modify intensive care unit-acquired Enterobacteriaceae bacteraemia mortality and discharge? *J Hosp*
412 *Infect* 2017;96:23-8.
- 413

414 **Box 1.** A directed acyclic graph (DAG) to illustrate the definition of confounder and mediator.

415




416

417 **Footnote:** Arrows indicate the direction of a causal relationship.

418

419 **Figure 1.** Flow chart of patients identified in the hospital microbiology database and included in the
420 analysis.

421



422

423


424 **Table 1** Characteristics of patients with hospital-acquired bloodstream infection related to
 425 *Acinetobacter* spp..

	No delays in concordant antibiotic treatment (n=521)	One-day of delay in concordant antibiotic treatment (n=224)	Two-day of delay in concordant antibiotic treatment (n=119)	Three or more days of delay in concordant antibiotic treatment (n=339)
Age (years)	54 (26-69)	57 (12-70)	51 (14-69)	54 (6-70)
Female gender	212 (40.7%)	103 (46.0%)	56 (47.1%)	143 (42.2%)
Fluoroquinolone-resistance	309 (59.3%)	191 (85.3%)	93 (78.2%)	266 (78.5%)
Carbapenem-resistance	312 (59.9%)	195 (87.1%)	103 (86.6%)	286 (84.4%)
Multi-drug resistance	364 (69.9%)	206 (92.0%)	103 (86.6%)	302 (89.1%)
Age-adjusted CCI score on admission	2 (0-4)	2 (0-5)	2 (0-4)	2 (0-4)
Patients with vasopressor prescription on the day of blood sample collected for culture	211 (40.5%)	129 (57.6%)	50 (42.0%)	103 (30.4%)
Patients with vasopressor prescription on the second day of blood sample collected for culture	176 (38.7%) ^a	22 (40.7%) ^c	43 (36.1%)	117 (34.5%)
Patients with vasopressor prescription on the third day of blood sample collected for culture	133 (34.1%) ^b	17 (34.7%) ^d	15 (38.5%) ^e	97 (28.6%)
Patients admitted to ICU on the day of hospitalization	285 (54.7%)	159 (71.0%)	72 (60.5%)	162 (47.8%)
Patients in the ICU on the day of blood sample collected for culture	304 (58.3%)	156 (69.6%)	70 (58.8%)	191 (56.3%)
Overall in-hospital mortality	194 (37.2%)	137 (61.2%)	59 (49.6%)	120 (35.4%)

30-day in-hospital mortality since blood collection	173 (33.2%)	133 (59.4%)	59 (49.6%)	102 (30.1%)
Length of hospital stay since admission to blood sample collected for culture (days)	8 (5-18)	7 (5-14)	8 (5-14)	9 (5-16)
Days on antibiotic prior blood sample collection	8 (5-15)	5 (0-10)	7 (3-12)	7 (4-14)

426 ^aDenominator is 455 as 66 patients with no delays in concordant antibiotic treatment were discharged
427 from the hospital or died after t=0. ^bDenominator is 390 as 65 more patients with no delays in
428 concordant antibiotic treatment were discharged from the hospital or died after t=1. ^cDenominator is 54
429 as 170 patients with a one-day delay in concordant antibiotic treatment were discharged from the
430 hospital or died after t=0. ^dDenominator is 49 as 5 more patients with a one-day delay in concordant
431 antibiotic treatment were discharged from the hospital or died after t=1. ^eDenominator is 39 as 55
432 patients with a two-day delay in concordant antibiotic treatment were discharged from the hospital or
433 died after t=0.
434 Age, CCI score, length of hospital stay since admission to blood collection, and days on antibiotic prior
435 blood collection are median (IQR), and other data is n (%). ICU=intensive care unit. CCI=Charlson
436 Comorbidity Index Score; defined using ICD10 scores.¹⁸ Multidrug resistance is defined as non-
437 susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories.¹⁹
438

439 **Figure 2.** Regimen assignment, all-cause 30-day in-hospital mortality, and discharge patterns over
 440 three days post blood sample collection of the study cohort.



Unobserved
 Concordant antibiotic treatment
 Discordant antibiotic treatment
 *Groups of patients that are discharged or died before reaching the third day of antibiotic treatment (t=2)

441

442

443 **Footnote:** The four regimens of treatment strategy are no delays in concordant antibiotic treatment

444 (green box), a one-day delay (pink box), a two-day delay (blue box), and three or more days of delays

445 (orange box).

446

447

448 **Table 2.** Estimated probability of 30-day mortality under each exposure group.

	Crude 30-days in-hospital all-cause mortality (n)	Expected 30-days mortality (95% CI) under each treatment regimen*
No delays in concordant antibiotic treatment (n=521)	33.2% (173)	39.7% (32.3%-47.2%)
A one day of delay in concordant antibiotic treatment (n=224)	59.4% (133)	42.7% (29.8%-55.7%)
A two day of delay in concordant antibiotic treatment (n=119)	49.6% (59)	51.0% (38.9%-63.2%)
Three or more days of delays in concordant antibiotic treatment (n=339)	30.1% (102)	40.9% (36.0%-45.7%)

449 *Estimated from a marginal structural model with stabilized IPWs.